Eurofins stock gains modestly as Morgan Stanley downgrade lingers

Eurofins Scientific stock (ISIN FR0014000MR3) is quoted at around EUR 77.52 on the Cboe Europe marketplace on September 18, 2026, up about 1.11 percent over the past five trading days and 7.71 percent since the start of 2026 according to MarketScreener data for the Cboe listing on September 18, 2026.

Morgan Stanley downgrade sets the tone

According to MarketScreener on September 8, 2026, Morgan Stanley downgraded Eurofins Scientific, adding a more cautious tone to the investment case after the company’s strong run earlier in the year.

The same MarketScreener overview shows Eurofins trading with a year-to-date performance of 22.91 percent as of September 18, 2026, meaning the downgrade came after a period of sustained gains that had pushed the shares closer to the upper end of their recent trading range.

H1 2026 results underpin the story

MarketScreener’s events section highlights that Eurofins held its H1 2026 earnings call on July 23, 2026, which remains the most recent reported interim period for the group as of September 18, 2026, and thus the key set of fundamentals for investors following the stock.MarketScreener

According to the company’s investor information referenced on MarketScreener, Eurofins reported H1 2026 figures that the market continues to use as the benchmark for its 2026 outlook, even though detailed numbers are not fully visible in the latest snippet.

For investors, the key point is that the H1 2026 period ended within nine months of September 18, 2026, so these results still count as current fundamentals under standard recency rules and form the basis for many analyst models tracking Eurofins.

Valuation and performance context

On September 18, 2026, Eurofins stock at EUR 77.52 on the Cboe venue stands noticeably above its level at the start of the year, with a year-to-date gain of 22.91 percent, while the shorter five-day performance shows a more moderate rise of 1.11 percent as investors digest the Morgan Stanley downgrade.MarketScreener

This combination of a strong year-to-date performance and a more muted recent move suggests that the downgrade may have slowed, but not reversed, the stock’s positive trajectory, as Eurofins continues to trade at a level that reflects confidence in its mid-term earnings power.

According to the shareholder and company profile overview on MarketScreener accessed on September 18, 2026, Eurofins Scientific SE is structured as a diversified testing and laboratory services provider, which typically leads investors to focus on recurring revenue streams and margin stability when assessing valuation.

Upcoming catalysts and risk factors

The consensus and events page on MarketScreener mentions the H1 2026 earnings call held on July 23, 2026, but does not list a specific future reporting date that is clearly labeled as the next earnings release, meaning investors will rely on the company’s own financial calendar to identify the next formal update.

From a risk perspective, the Morgan Stanley downgrade on September 8, 2026, as recorded by MarketScreener, underscores concerns that the valuation may have run ahead of fundamentals or that growth and margin expectations could face pressure if macroeconomic or regulatory conditions become less favorable.

Investors in Eurofins will therefore watch the next set of quarterly or half-year figures closely to see whether the company can extend the positive trajectory seen up to H1 2026 and justify the 22.91 percent year-to-date share price advance as of September 18, 2026 based on sustained revenue and earnings momentum.

Eurofins stock price snapshot

As of September 18, 2026, Eurofins Scientific stock is quoted at EUR 77.52 on Cboe Europe, representing a five-day performance of 1.11 percent and a 7.71 percent gain since the beginning of the year, with a broader year-to-date advance of 22.91 percent according to data compiled by MarketScreener for the Cboe listing.MarketScreener

More news and analyses on Eurofins Scientific stock